Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns

This article was originally published in Start Up

Executive Summary

As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.

You may also be interested in...

Private Adimab Breaks $1 Billion Valuation, Offers VCs Liquidity Through $100 Million Secondary

A secondary offering by the privately held antibody discovery play has valued the company at more than a billion dollars and allowed its venture investors to cash in some or all of their positions. Meanwhile, Adimab continues to announce new partnerships including a monoclonal and bispecific antibody discovery pact with Sanofi.

Inimitable Ablexis Delivers Mice To Partners, Multiples To Investors

Antibody platform play Ablexis has successfully built its technology, fulfilled a commitment to its pharmaceutical partners, triumphed in a lawsuit brought by one of biotech’s big boys, and lined the pockets of its investors. Surprisingly, it has no imitators.

Adimab Inside: Polaris, Orbimed Back Antibody Attack On Novel Alzheimer’s Biology

Alzheimer’s-focused Alector combines its scientific founders’ biological insight with antibody discovery technology from Adimab, allowing Adimab’s backers and executives to pursue multiple but distinct bets on the success of their platform.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts